Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Carcinoma, Basal Cell 3Pancreatic Neoplasms 2Neoplasms 2Basal Cell Nevus Syndrome 2Head and Neck Neoplasms 1Chondrosarcoma 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Filgrastim 5Ifosfamide 3Docetaxel 3Carboplatin 3belinostat 2Sunitinib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Gemcitabine 2Etoposide 2Epirubicin 2Doxorubicin 2toripalimab 1temsirolimus 1tanespimycin 1resiquimod 1poly ICLC 1perifosine 1pegfilgrastim 1pazopanib 1liposomal doxorubicin 1ivosidenib 1etoposide phosphate 1enasidenib 1apatinib 1angiotensin I (1-7) 1alanosine 1Vincristine 1Topotecan 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Chondrosarcoma × IPI-926 × Clear all
NCT01609179 2012-11-14

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Infinity Pharmaceuticals, Inc.

Phase NA Completed
9 enrolled
DermatologicSarcoma

Carcinoma, Basal Cell, Chondrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡